（向上滑动👆）
1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. [Crossref] [PubMed]
2.Al-Quteimat OM, Amer AM. A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care. J Oncol Pharm Pract 2020;26:1452-60. [Crossref] [PubMed]
3.Parafianowicz P, Krishan R, Beutler BD, et al. Myositis - A common but underreported adverse effect of osimertinib: Case series and review of the literature. Cancer Treat Res Commun 2020;25:100254. [Crossref] [PubMed]
4.Cabral BMI, Edding SN, Portocarrero JP, et al. Rhabdomyolysis. Dis Mon 2020;66:101015. [Crossref] [PubMed]
5.Stahl K, Rastelli E, Schoser B. A systematic review on the definition of rhabdomyolysis. J Neurol 2020;267:877-82. [Crossref] [PubMed]
6.Akamatsu H, Katakami N, Okamoto I, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci 2018;109:1930-8. [Crossref] [PubMed]
7.Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17:1643-52. [Crossref] [PubMed]
8.Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017;35:1288-96. [Crossref] [PubMed]
9.Fujioka S, Kitajima T, Itotani R. Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib. J Thorac Oncol 2018;13:e137-9. [Crossref] [PubMed]
10.Sugimoto H, Matsumoto S, Tsuji Y, et al. Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature. J Oncol Pharm Pract 2022;28:489-94. [Crossref] [PubMed]
11.Deng W, Wang K, Jiang Y, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2022;12:e062036. [Crossref] [PubMed]
12.Zhou K, Zhao S, Guo W, et al. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e18771. [Crossref] [PubMed]
13.Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:1655-69. [Crossref] [PubMed]
14.West HL, Moon J, Wozniak AJ, et al. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 2018;19:84-92. [Crossref] [PubMed]
15.Zappa F, Droege C, Betticher D, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer 2012;78:239-44. [Crossref] [PubMed]
16.Ninomiya T, Nogami N, Kozuki T, et al. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. Jpn J Clin Oncol 2021;51:1269-76. [Crossref] [PubMed]
17.Akamatsu H, Toi Y, Hayashi H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. JAMA Oncol 2021;7:386-94. [Crossref] [PubMed]
18.Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA Oncol 2020;6:1048-54. [Crossref] [PubMed]
19.Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019;20:625-35. [Crossref] [PubMed]
20.Leroy MC, Perroud J, Darbellay B, et al. Epidermal growth factor receptor down-regulation triggers human myoblast differentiation. PLoS One 2013;8:e71770. [Crossref] [PubMed]
21.Vishwanathan K, Dickinson PA, So K, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol 2018;84:1156-69. [Crossref] [PubMed]
22.Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther 2019;12:5467-84. [Crossref] [PubMed]
23.Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013;18:1004-12. [Crossref] [PubMed]
24.Harvey RD, Aransay NR, Isambert N, et al. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. Br J Clin Pharmacol 2018;84:2877-88. [Crossref] [PubMed]
25.Ramamoorthy SK, Marangolo M, Durrant E, et al. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. Leuk Lymphoma 2006;47:747-50. [PubMed]
26.Tauber M, Cohen R, Laly P, et al. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. Clin Rheumatol 2019;38:601-2. [Crossref] [PubMed]
27.Sakellaropoulou A, Theofilos D, Bisirtzoglo D. A rare adverse effect while treating lung adenocarcinoma. Pneumon 2015;1:262-5.
